Mariani G, Cei A, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Lucca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI.
Tumor targeting potential and metabolism of 5-[125]iodo-2-deoxyurdine injected intratumorally in patients with gastrointestinal or breast cancers. J Nucl Biol Med. 1992; 154-7.
Tumor targeting potential and metabolism of 5-[125]iodo-2-deoxyurdine injected intratumorally in patients with gastrointestinal or breast cancers
Demetri GD, Heinrich MC, George S, Manola J, Morgan JA, Desai J, St. Amand J, Cohen DP, Scigalla P, Manning WC, Cherrington JM, McCarthy TJ, Corless CL, Fletcher JA, Fletcher CDM, Van den Abbeele AD.
Biological activity of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal Stromal tumor (GIST)refractory to imatinib mesylate. AACR. 2003; 44:967.
Biological activity of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal Stromal tumor (GIST)refractory to imatinib mesylate
Moore SC, El Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE.
Relative lesion detectability in 3D vs. 2D dedicated multi-ring PET. IEEE meeting 2000, Lyon, France. 2000.
Relative lesion detectability in 3D vs. 2D dedicated multi-ring PET
VanSonnenberg E, Silverman SG, Shankar S, Tuncali K, Van den Abbeele AD, Meyerovitz M, Whang E.
Strategies and rationale for radiologic tumor ablation.
Large and multiple hepatic Lesions. Strategies and rationale for radiologic tumor ablation. 2000.
Division of Nuclear Medicine, Beth Israel Hospital, Harvard Medical School.
Parathyroid scintigraphy. Division of Nuclear Medicine, Beth Israel Hospital, Harvard Medical School. 1986; 7(2).
Wagenaar DJ, Zimmerman RE, Hill TC, Kolodny GM, Van den Abbeele AD.
American Association of Physicists in Medicine a 39th Annual Meeting and Exhibition.
Comparison of Dual-Head Gamma Camera System Sensitivity at 511 KeV using a Distance-Dependent Method. American Association of Physicists in Medicine a 39th Annual Meeting and Exhibition. 1997.
Comparison of Dual-Head Gamma Camera System Sensitivity at 511 KeV using a Distance-Dependent Method
A day in the life of the Dana-Farber Cancer Institute. 2001.
A day in the life of the Dana-Farber Cancer Institute
George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Richie J, Kantoff P and Bubley G.
A Pilot study of Imatinib Mesylate (Gleevec) prior to prostatectomy in men with newly diagnosed prostate cancer. CaPCURE Scientific Retreat. 2002.
A Pilot study of Imatinib Mesylate (Gleevec) prior to prostatectomy in men with newly diagnosed prostate cancer
American Association of Physicists in Medicine 39th Annual Meeting and Exhibition. Milwaukee, WI.
Comparison of Dual-Head Gamma Camera System Sensitivity at 511 keV using a Distance-Dependent Method. American Association of Physicists in Medicine 39th Annual Meeting and Exhibition. Milwaukee, WI. 1997.
Comparison of Dual-Head Gamma Camera System Sensitivity at 511 keV using a Distance-Dependent Method
Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S
Annals of the New York Academy of Sciences
Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer. Ann N Y Acad Sci. 1993 Nov 30; 698:204-11.
Tumor targeting potential and metabolism of 5-[125I]iodo-2'-deoxyuridine injected intratumorally in patients with breast cancer.
Kassis AI, Tumeh SS, Wen PY, Baranowska-Kortylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garada BM, DeSisto WC, Bailey NO, Castronovo FP, Mariani G, Black PM, Adelstein SJ
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor. J Nucl Med. 1996 Apr; 37(4 Suppl):19S-22S.
Intratumoral administration of 5-[123I]iodo-2'-deoxyuridine in a patient with a brain tumor.
Otero HJ, Yap JT, Patak MA, Erturk SM, Israel DA, Johnston CJ, Sakellis C, Rybicki FJ, Van den Abbeele AD, Ros PR
Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial. AJR Am J Roentgenol. 2009 Aug; 193(2):326-32.
Evaluation of low-density neutral oral contrast material in PET/CT for tumor imaging: results of a randomized clinical trial.
Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422.
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice.
Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol. 2011 May; 59(5):856-62.
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK
Annals of oncology : official journal of the European Society for Medical Oncology
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol. 2009 Nov; 20(11):1848-53.
Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH
Hereditary cancer syndromes: a radiologist's perspective. AJR Am J Roentgenol. 2011 Dec; 197(6):W1001-7.
Hereditary cancer syndromes: a radiologist's perspective.
Sheehy N.P.; Israel D.; Ramaiya N.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA
18FDG-PET/CT in Soft Tissue Sarcoma: Looking Beyond GIST. American Journal of Roentgenology(AJR). 2007; 188(5):E429-A191-A195.
18FDG-PET/CT in Soft Tissue Sarcoma: Looking Beyond GIST
El Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF.
Impact of acquisition geometry and lesion size on tumor detectability in patient whole body PET: A channelized hotelling observer study. IEEE meeting. 2002.
Impact of acquisition geometry and lesion size on tumor detectability in patient whole body PET: A channelized hotelling observer study
Uncovering Cancer. The use of radioactive tracers. 2000.
Uncovering Cancer. The use of radioactive tracers
Makrigiorgos GM, Baranowska-Kortylewicz J, Van den Abbeele AD, Ito S, Vinter DW, Adelstein SJ, Kassis AI
Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry. Radiat Prot Dosim. 1990; 31:319-24..
Microscopic spatial inhomogeneity of radiopharmaceutical deposition in mammalian tissues: dosimetry at the cellular level and comparison with conventional dosimetry
George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60.
Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD
Imaging of extraosseous myeloma: CT, PET/CT, and MRI features. AJR Am J Roentgenol. 2010 Nov; 195(5):1057-65.
Imaging of extraosseous myeloma: CT, PET/CT, and MRI features.
Ng AK, Bernardo MV, Silver B, Van Den Abbeele A, Stevenson MA, Fisher DC, Mauch PM
International journal of radiation oncology, biology, physics
Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2005 Jan 01; 61(1):175-84.
Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.
Tumeh SS, Carvalho PA, van den Abbeele AD, Maguire JH, Rauh DA, Neptune M, Kassis AI
Journal of nuclear biology and medicine (Turin, Italy : 1991)
Detection of focal infection by 111In-human polyclonal IgG. J Nucl Biol Med (1991). 1991 Jan-Mar; 35(1):4-9.
Detection of focal infection by 111In-human polyclonal IgG.
Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele A.
Lymphoscintigraphy. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele A. 2000; 369-374.
Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI
American journal of obstetrics and gynecology
Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol. 1989 Nov; 161(5):1206-12.
Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125.
Friedberg JW, Canellos GP, Neuberg D, Kim H, Mauch P, Van den Abbeele.
International Lymphoma Conference, Lausanne
A prospective blinded comparison of positron emission tomography(PET)with gallium/SPECT scintigraphy in the staging and follow-up of patients with de novo Hodgkin's disease. International Lymphoma Conference, Lausanne. 2001.
A prospective blinded comparison of positron emission tomography(PET)with gallium/SPECT scintigraphy in the staging and follow-up of patients with de novo Hodgkin's disease
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD.
American Society of Clinical Oncology (ASCO)Conference. New Orleans, LA
Clonal evaluation of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions. American Society of Clinical Oncology (ASCO)Conference. New Orleans, LA. 2004.
Clonal evaluation of resistance to imatinib in patients with gastrointestinal stromal tumor (GIST): Molecular and radiologic evaluation of new lesions
Thallium-201 scintigraphy in low grade non-Hodgkin's lymphoma. J Nucl Med. 1996; 37:P258.
Thallium-201 scintigraphy in low grade non-Hodgkin's lymphoma
Inflammation and infection. Pediatric Nuclear Medicine. 1995; 540-549.
EI Fakhri G, Badawi RD, Santos PA, Moore SC, Van den Abbeele AD, Kijewski MF.
Impact of acquisition geometry and size on tumor detectability in patient whole body PET:. A Channelized hotelling observer study. 2002.
Impact of acquisition geometry and size on tumor detectability in patient whole body PET:
Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis Al.
Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia
A three-step procedure for the targeting of tumors using the avidin-biotin system. Australia/New Zealand Society of Nuclear Medicine Scientific Meeting, Canberra, Australia. 1993.
A three-step procedure for the targeting of tumors using the avidin-biotin system
Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele.
Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 235-246.
Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD
Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):217-22.
Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location.
Bindra J, Israel DA, Van den Abbeele AD.
Radiological Society of North America (RSNA) Conference. Chicago, IL
Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging
Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
Makrigiorgos GM, Ito S, Baranowska-Kortylewicz J, Vinter DW, Iqbal A, Van den Abbeele AD, Adelstein SJ, Kassis AI
Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications. J Nucl Med. 1990 Aug; 31(8):1358-63.
Inhomogeneous deposition of radiopharmaceuticals at the cellular level: experimental evidence and dosimetric implications.
Protti A, Jones KL, Bonal DM, Qin L, Politi LS, Kravets S, Nguyen QD, Van den Abbeele AD
Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model. PLoS One. 2018; 13(7):e0200611.
Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model.
Janicek MJ, Van den Abbeele AD, Hollenberg NK, Kassis AI, Holman BL, Tumeh SS
Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography. Invest Radiol. 1990 Sep; 25(9):988-93.
Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography.
Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St Amand M, Baum C, Demetri GD.
American Soceity of Clinical Oncology (ASCO) Conference.
Effects of cesssation of imatinib mesylate (IM) therapy in patients (pts) with IM-refactory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Soceity of Clinical Oncology (ASCO) Conference. 2004.
Effects of cesssation of imatinib mesylate (IM) therapy in patients (pts) with IM-refactory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning
McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Lake-Willcutt B, Posner MR.
The Second International Chicago Symposium on Malginancies of the Chest and Head & Neck.
The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The Second International Chicago Symposium on Malginancies of the Chest and Head & Neck. 2001; abst. 76.
The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck
Mariani G, Giuliani L, Baranowska-Kortylewicz J, Collecchi P, Meucci G, Di Luca L, Viacava P, Van den Abbeele AD, Bevilacqua G, Salvadori PA, Adelstein SJ, Kassis AI.
Radioactive isotopes in clinical medicine and research.
Intratumoral injection of 5[123]iodo-2-dexyuridine in patients with breast cancer. In Hofer R, Bergmann H, Sinzinger H, eds. Radioactive isotopes in clinical medicine and research. 1993; 188-93.
Intratumoral injection of 5[123]iodo-2-dexyuridine in patients with breast cancer. In Hofer R, Bergmann H, Sinzinger H, eds
Medical Progress, Esophageal Cancer. New Engl. J. Med.
Medical Progress, Esophageal Cancer. New Engl. J. Med. 2003.
Medical Progress, Esophageal Cancer. New Engl. J. Med
Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, Kulke MH, Chan JA, Jacene HA, Van den Abbeele AD
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244.
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.
The American Journal of Oncology Reivew.
A New Role for PET Scanning. The American Journal of Oncology Reivew. 2003; 367-368.
Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and El Fakhri G.
IEEE Medical Imaging Conference. Portland, OR
Evaluation of a Model Based Scatter Correction in Clinical 3D PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
Evaluation of a Model Based Scatter Correction in Clinical 3D PET
L. Syrkin, D. J. de Vries, G. Lefever, T. Locascio, Y. Kuzuhara, A. D. Van den Abbeele, J. T. Yap, Nuclear Medicine/PET, Dana-Farber Cancer Institute, Boston, Massachusetts.(333352)
Deveolpment of a PET/CT database of patient information and scanning parameters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):199P/701.
Deveolpment of a PET/CT database of patient information and scanning parameters
Mariani G, Van den Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AL.
Nuclear medicine: trends and possibilities in nuclear medicine.
Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line. Nuclear medicine: trends and possibilities in nuclear medicine. 1989; 602-605.
Internalization of monoclonal 3G5-IgM by a rat insulinoma cell line
Classification of upper extremity lymphedema via lymphoscintigraphy. J Nucl Med. 1996; 37:P261.
Classification of upper extremity lymphedema via lymphoscintigraphy
Wagenaar DJ, Golden E, Van den Abbeele AD, Kolodny GM.
European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer, Groningen University Hospital, The Netherlands
Determination of the visibility of simulated lesions in background with 511 keV SPECT. European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer, Groningen University Hospital, The Netherlands. 1996.
Determination of the visibility of simulated lesions in background with 511 keV SPECT
DePrimo SE, Wong LM, Nicholas SL, Manning WC, O'Farrell AM, Amand M, McConarty B, Topciu R, Kazanovic A, Van den Abbeele AD, Demetri GD, Cherrington JM.
Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal Stromal tumor (GIST) receiving the novel kinases inhibitor SU11248: Correlative analysis of blood and plasma biomarkers. AACR. 2003; 44:587.
Decreases in circulating levels of soluble KIT in patients with imatinib-resistant gastrointestinal Stromal tumor (GIST) receiving the novel kinases inhibitor SU11248: Correlative analysis of blood and plasma biomarkers
Monoclonal antibodies: A review of the basics.
Monoclonal antibodies: A review of the basics. 1994.
Monoclonal antibodies: A review of the basics
Van den Abbeele A, Solorzano C, Jones AG, Beardsley DS, Treves S, Davison A.
Leukocyte labeling with isonitrile complexes of technetium-99m. J Nucl Med. 1985; 26:P131.
Leukocyte labeling with isonitrile complexes of technetium-99m
Molecular-genetic imaging: current and future perspective.
Molecular-genetic imaging: current and future perspective. 2003.
Molecular-genetic imaging: current and future perspective
N. Sheehy, I. A. David, A. D. Van den Abbeele, Radiology, Dana-Farber Cancer Institute, Boston, Massachusetts.(333139)
Diagnosis of venous obstruction and thrombosis by radionuclinde venography in patients with central venous catheters. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):212P/1019.
Diagnosis of venous obstruction and thrombosis by radionuclinde venography in patients with central venous catheters
Weadock KS, Anderson LL, Van den Abbeele AD, Makrigiorgos G, Kassis Al.
Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA
Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 98.
Radiolabeled biodegradable membranes for radioimmunotherapy
Van den Abbeele AD, Badawi RD, Manola J, Morgan J, Desai J, Kazanovicz A, St. Amand M, Baum C, Demetri GD.
American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA.
Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
Effects of cessation of imatinib mesylate therapy in patients with IM-refractory gastrointestinal stromal tumors (GIST)as visualized by FDG-PET scanning
Large and multiple hepatic lesions: Strategies and rationale for radiologic tumor ablation. RSNA Annual Meeting. 2000.
Large and multiple hepatic lesions: Strategies and rationale for radiologic tumor ablation
Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD
Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011 Jan; 196(1):117-22.
Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.
Teaching Atlas of Nuclear Medicine. 2000.
Lin NU, Carey LA, Liu MC, Come SE, Bullitt E, Van den Abbeele AD, Li X, Hochberg FH, Winer EP
American Society of Clinical Oncology (ASCO)
Pahe II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. American Society of Clinical Oncology (ASCO). 2006; 24:3s.
Pahe II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD
Tumor Ablation: Principles and Practice.
Tumor Ablation: Principles and Practice. 2005; 121-134..
Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA
Missed Metastases-Causes and Clinical Relevance. American Journal of Roentgenology(AJR). 2007; 188(5):E145-A115.
Missed Metastases-Causes and Clinical Relevance
Van den Abbeele AD, Baranowska- Kortylewicz J, Mariani G, Adelstein SJ, Kassis AI.
Presented at the Second International Symposium on Biophysical Aspect of Auger Processes, Amherst.
Diagnostic and therapeutic applications of the Auger electrons-emitting 5-[123/125/]iodo-2-deoxyuridine in cancer. Presented at the Second International Symposium on Biophysical Aspect of Auger Processes, Amherst. 1991.
Diagnostic and therapeutic applications of the Auger electrons-emitting 5-[123/125/]iodo-2-deoxyuridine in cancer
Sundell HW, Rojas J, Grogaard J, Mohan P, Engelhardt B, Van den Abbeele A, Harris TR, Brigham KL.
The physiological development of the fetus and newborn.
Lung lymph studies in newborn lambs with hyaline membrane disease. The physiological development of the fetus and newborn. 1985; 331-335.
Lung lymph studies in newborn lambs with hyaline membrane disease
Tumor and Inflammatory conditions. 1996.
Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Manning WC, DePrimo SE, O'Farrell AM, Bello CL, Cohen DP, Scigalla P, Fletcher JA and Demetri GD.
ISMRM Workshop on Cellular and Molecular Imaging in Diagnostics and Therapy. Orlando, FL
Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Pharmacodynamic evaluation using FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. ISMRM Workshop on Cellular and Molecular Imaging in Diagnostics and Therapy. Orlando, FL. 2003.
Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Pharmacodynamic evaluation using FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers
Weadock KS, Anderson LL, Van den Abbeele AD, Maktrigiorgos G, Kassis AI.
Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer.
Radiolabeled biodegradable membranes for radioimmunotherapy. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1989; 98.
Seeing into cells: the promise of in vivo molecular imaging in oncology.
Seeing into cells: the promise of in vivo molecular imaging in oncology. 2005.
Seeing into cells: the promise of in vivo molecular imaging in oncology
Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Bacum C, Maki R, Heinrich MC.
American Society of Clinical Oncology (ASCO)Conference.
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by stromal tumor (GIST). American Society of Clinical Oncology (ASCO)Conference. 2004.
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by stromal tumor (GIST)
Lechpammer S, Tetrault RJ, Badawi RD, Van den Abbeele
PET imaging and treatment evaluation in cancer patients.
PET imaging and treatment evaluation in cancer patients. 2002.
PET imaging and treatment evaluation in cancer patients
Gangopadhyay A, Saravis CA, van den Abbeele AD, Kassis AI
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
pI-dependent isolation of antibody isoforms by semipreparative isoelectric focusing. Q J Nucl Med. 1995 Jun; 39(2):129-33.
pI-dependent isolation of antibody isoforms by semipreparative isoelectric focusing.
Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI
Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med. 1996 Feb; 37(2):315-20.
Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer.
Radiographic Evaluation of Cancer. Atlas of Diagnostic Oncology. 2003; 5-26.
Radjahyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD.
Radiological Society of North America (RSNA) Conference.
Prospective comparison of imaging finding in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. . 2003.
Prospective comparison of imaging finding in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD
Johnston C.; Ramaiya N.; Khosa F.; Van den Abbeele A. Dana-Farber Cancer Institute, Boston, MA
Radiological Response and Toxicity of the New Targeted Molecular Therapies for Cancer-What the Radiologist Needs to Know. American Journal of Roentgenology(AJR). 2007; 188(5):E419 A191-A195.
Radiological Response and Toxicity of the New Targeted Molecular Therapies for Cancer-What the Radiologist Needs to Know
Van den Abbeele AD, Israel DA, Lechpammer S, Badawi RD.
Pet Imaging: Tumor Ablation: Principles and Practice. 2003.
Pet Imaging: Tumor Ablation: Principles and Practice
The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST).
The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST). 2004.
The era of molecular therapy: redifining the treatment of gastrointestinal stromal tumors (GIST)
Van den Abbeele AD, Badawi RD, Cliche JP, Israel D, Dimitrijevic S, Demetri G.
Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology. 2002; 225:P424.
Response to imatinib mesylate (Gleevec) therapy in patients with advanced gastrointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT
Grogaard J, Van den Abbeele A, Sundell H
Journal of applied physiology (Bethesda, Md. : 1985)
Effect of alcohol on apnea reflexes in young lambs. J Appl Physiol (1985). 1985 Aug; 59(2):420-5.
Effect of alcohol on apnea reflexes in young lambs.
Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol. 2010 Aug; 195(2):281-9.
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.
Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med. 2012 Apr; 53(4):567-74.
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Mariani G, Collecchi P, Giuliani L, Baranowska-Kortylewicz J, Di Luca L, Meucci G, Viacava P, Van den Abbeele AD, Salvadori PA, Di Sacco S, Adelstein SJ, Bevilacqua G, Kassis AI.
Tumor targeting potential and metabolism of 5-[125]iodo 2-deoxyuridine injected intratumorally in patients with breast Cancer. Ann NY Acad sc. 1993; 698:204-11.
Tumor targeting potential and metabolism of 5-[125]iodo 2-deoxyuridine injected intratumorally in patients with breast Cancer
Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke, C, von Mehren M, Joensuu H, Dimitrijevic S, Silberman S, Demetri GD and Van den Abbeele AD.
Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA.
Use of Computerized Tomography as an Early Prognostic Indicator of Response to Imatinib Mesylate in Patient with Gastrointestinal Stromal Tumors (GIST). Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. 2004.
Use of Computerized Tomography as an Early Prognostic Indicator of Response to Imatinib Mesylate in Patient with Gastrointestinal Stromal Tumors (GIST)
New core facility provides a common home for high-tech analysis of tumor images. Inside the Institute. 2007; 12(5):1.
New core facility provides a common home for high-tech analysis of tumor images
FDG-PET as a key tool in the diagnosis and monitoring of GIST. In first Successful Treatment for GIST. 2002.
FDG-PET as a key tool in the diagnosis and monitoring of GIST
McCollum AD, Van den Abbeele AD, Haddad Rl, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR.
Sixth Research Workshop on the Biology,Prevention, and Treatment of Head and Neck Cancer.
The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology,Prevention, and Treatment of Head and Neck Cancer. 2002.
The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck
Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, Van den Abbeele AD, Mariani G, Ito S.
Potential for tumor therapy with iodine-125 labeled immunoglobulins. Nucl Medicine Biol. 1991; 18:43-4.
Potential for tumor therapy with iodine-125 labeled immunoglobulins
The role of PET in patients with cancer. 2001.
Shankar S, Desai J, Potter A, George S, Sherwood GK, Israel D, Dipiro P, Van den Abbeele AD, vanSonnenberg E, Demetri G.
Novel patterns of progression following initial response to Imatinib in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2003; 22:230A.
Novel patterns of progression following initial response to Imatinib in patients with malignant gastrointestinal stromal tumors (GIST)
Van den Abbeele AD, Wen PYC, Aaronson RA, Makrigiorgos GM, Morris JH, Baranowska-Kortylewicz J, Lampson LA, Black PM, Adelstein SJ, Kassis Al.
Autoradiographic validation of 5-[123/125/] iodo-2'-deoxyurdine as a diagnostic and therapeutic agent for brain tumors. J Nucl Med,. 1990; 31(766).
Autoradiographic validation of 5-[123/125/] iodo-2'-deoxyurdine as a diagnostic and therapeutic agent for brain tumors
Van den Abbeele AD, Melenevsky Y, de Vries DJ, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri GD
American Society of Clinical Oncology (ASCO); Orlando, FL.
Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). American Society of Clinical Oncology (ASCO); Orlando, FL. 2005.
Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST)
Van den Abbeele AD, Badawi RD, Cliche JP, Janicek M, Tetrault R, Spangler T, Potter A, Merriam P, Silberman S, Dimitrijevic S, Demetri GD.
F-FDG-PET predicts response to Imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2002; 21:P403a.
F-FDG-PET predicts response to Imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST)
Desai J, Shankar S, Heinrich MC, Fletcher JA, George S, Van den Abbeele AD, vanSonnenberg E, Demetri GD.
A CME newsletter publication covering key clinical issues in the management of GIST, including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium
A CME newsletter publication covering key clinical issues in the management of GIST, including highlights from the 2003 CTOS annual meeting and Helsinki GIST symposium. 2004.
Blanke C, Joensuu H, Demetri G, Heinrich M, Roberts P, Eisenberg B, Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M.
Gastrointestinal Cancers Symposium; San Francisco, CA.
Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate. Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
Long-term follow up of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate
Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van den Abbeele A, Silverman SG, Demetri GD.
Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM)
El Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF.
Impact of patients size, Acquisition mode, reconstruction algorithm, and random and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
Impact of patients size, Acquisition mode, reconstruction algorithm, and random and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET
Desai J, Maki R, Heinrich MC, Fletcher JA, Ryan D, Morgan JA, St. Amand M, George S, Manola J, Baum C, Cohen DP, Corless CL, Fletcher CD, Van den Abbeele AD, Demetri GD
American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA.
Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2004.
Activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU011248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate
Borras-Boneu G, Knapp RC, Van den Abbeele AD, Kassis Al.
Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceedings of the Fourth International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, CA. 1989; 97.
Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts
Lee B, Abbott A, Davidson S, Syrkin L, LeFever G, Van den Abbeele AD
Centralized Clinical Trial Imaging Data Management: Practical Guidance from a Comprehensive Cancer Center's Experience. J Digit Imaging. 2019 10; 32(5):849-854.
Centralized Clinical Trial Imaging Data Management: Practical Guidance from a Comprehensive Cancer Center's Experience.
Divsion of Nuclear Medicine at the DFCI.
A Patient Guide to Nuclear Medicine at the Dana-Farber Cancer Institute. Divsion of Nuclear Medicine at the DFCI. 1996.
A Patient Guide to Nuclear Medicine at the Dana-Farber Cancer Institute
Van den Abbeele AD, Burrell SC, McCollum D, Spangler TA, Haddad RI, Norris CM, Tishler RB, Posner MR.
The role of FDG-PET in patients with squamous cell cancer of the head and neck after sequential induction chemotherapy and definitive chemoradiotherapy. J Nucl Med. 2002; 43:P73.
The role of FDG-PET in patients with squamous cell cancer of the head and neck after sequential induction chemotherapy and definitive chemoradiotherapy
Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri G
FDG-PET imaging demonstrates metabolic response to SU11248 (sunitinib malate) within 7 days in GIST patients resistant to or intolerant of imatinib mesylate. ICACT. 2006; 17:241.
FDG-PET imaging demonstrates metabolic response to SU11248 (sunitinib malate) within 7 days in GIST patients resistant to or intolerant of imatinib mesylate
Impact of patient size, acquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET. IEEE Medical Imaging Conference. Portland, OR. 2003.
Impact of patient size, acquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estimation in whole-body FDG-PET
Scrontium-89 radiotherapy for painful bony metastases.
Scrontium-89 radiotherapy for painful bony metastases. 1996.
Scrontium-89 radiotherapy for painful bony metastases
Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. 2000; 199-216.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE
Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
Major response to imatinib mesylate in KIT-mutated melanoma.
Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ
Clinical cancer research : an official journal of the American Association for Cancer Research
Considerations for the use of imaging tools for phase II treatment trials in oncology. Clin Cancer Res. 2009 Mar 15; 15(6):1891-7.
Considerations for the use of imaging tools for phase II treatment trials in oncology.
Souza FF, Otero HJ, Erturk M, Rybicki FJ, Ramaiya N, Van den Abbeele AD, Di Salvo DN
Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities. Ultrasound Q. 2009 Sep; 25(3):145-50.
Venous thrombosis in an outpatient oncologic center: distribution, type, and comorbidities.
Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol. 2010 Sep; 195(3):W221-8.
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 May 17; 119(20):4597-607.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Radjadhyaksha CD, D Neuberg S Li, Fischman AJ, Van den Abbeele AD.
Prospective comparison of imaging findings in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD. Radiological Society of North America (RSNA) Conference. Chicago, IL. 2003.
Prospective comparison of imaging findings in the lung, hilum and spleen on FDG-PET and GA-67 scintigraphy in patients with hodgkin's disease prior to and following chemotherapy with ABVD
Van den Abbeele AD, Lechpammer S, Tetrault RJ, Badawi RD.
Non-Hodgkin's Lymphomas. Nuclear Medicine. 2003.
Jacobsen E, Van den Abbeele AD, Neuberg D, Li S, Fisher DC, Friedberg J, Barnes AS, Yap JT, Kutok J, Freedman AS
Inhibiting TNF with etanercept in relapsed/refractory follicular lymphoma. American Society of Clinical Oncology (ASCO). 2006; 24:682s.
Inhibiting TNF with etanercept in relapsed/refractory follicular lymphoma
The Power of Positron Emission Tomography (PET). 2001.
The Power of Positron Emission Tomography (PET)
American Society of Clinical Oncology (ASCO) Conference
Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM). American Society of Clinical Oncology (ASCO) Conference. 2004.
Safety and efficacy of percutaneous Radio-Frequency Ablation (RFA)in patients (Pts) with metastatic gastrointestinal stromal tumor (GIST)with clonal evolution of lesions refractory to imatinib mesylate (IM)
Jerome and Nancy Kohlberg Professor of Medicine
Steven E. Seltzer, MD, Professor of Radiology
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer. Radiology. 2019 12; 293(3):704-706.
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.
von Mehren M, George S, Heinrich MC, Schuetze SM, Yap JT, Yu JQ, Abbott A, Litwin S, Crowley J, Belinsky M, Janeway KA, Hornick JL, Flieder DB, Chugh R, Rink L, Van den Abbeele AD
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. Clin Cancer Res. 2020 04 15; 26(8):1837-1845.
Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study.
Könik A, O'Donoghue JA, Wahl RL, Graham MM, Van den Abbeele AD
Theranostics: The Role of Quantitative Nuclear Medicine Imaging. Semin Radiat Oncol. 2021 01; 31(1):28-36.
Theranostics: The Role of Quantitative Nuclear Medicine Imaging.
Abousaway O, Rakhshandehroo T, Van den Abbeele AD, Kircher MF, Rashidian M
Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics. 2021; 5(1):90-112.
Noninvasive Imaging of Cancer Immunotherapy.
Jacene H, Liu M, Cheng SC, Abbott A, Dubey S, McCall K, Young D, Johnston M, Van den Abbeele AD, Overmoyer B
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study. J Nucl Med. 2022 Jan; 63(1):22-28.
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study.
Importance of 68Ga-FAPI PET/CT for Detection of Cancer. Radiology. 2022 04; 303(1):200-201.
Importance of 68Ga-FAPI PET/CT for Detection of Cancer.
Cancer imaging : the official publication of the International Cancer Imaging Society
Will ultra-extended field-of-view scanners be an expensive folly or the next clinical standard for PET/CT? Cancer Imaging. 2022 09 06; 22(1):49.
Will ultra-extended field-of-view scanners be an expensive folly or the next clinical standard for PET/CT?
Lopci E, Aide N, Dimitrakopoulou-Strauss A, Dercle L, Iravani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans AWJM, Weber WA, Van den Abbeele AD, Wahl RL, Scott AM, Pandit-Taskar N, Hicks RJ
Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors. Cancer Imaging. 2022 Dec 20; 22(1):73.
Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors.
McCall KC, Liu M, Cheng SC, Abbott A, Dubey S, Young D, Johnston M, Van den Abbeele AD, Overmoyer B, Jacene H
Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer. J Nucl Med Technol. 2023 Sep; 51(3):204-210.
Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. J Clin Oncol. 2023 11 01; 41(31):4829-4836.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
Mehrtash A, Ziegler E, Idris T, Somarouthu B, Urban T, LaCasce AS, Jacene H, Van Den Abbeele AD, Pieper S, Harris G, Kikinis R, Kapur T
Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision. Comput Med Imaging Graph. 2024 01; 111:102312.
Evaluation of mediastinal lymph node segmentation of heterogeneous CT data with full and weak supervision.
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD
Radiographics : a review publication of the Radiological Society of North America, Inc
What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach.
Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.
O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, Van den Abbeele AD
Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence. Cancer Imaging. 2013 Dec 30; 13(4):626-32.
Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.
Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014 Mar 01; 120(5):711-21.
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist. 2014 May; 19(5):507-14.
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2014 Apr 20; 32(12):1202-9.
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014 Jul; 2(7):632-42.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA
Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.
Shinagare AB, O'Neill AC, Cheng S, Somarouthu B, Tirumani SH, Nishino M, Van den Abbeele AD, Ramaiya NH
Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up. Radiology. 2015 Dec; 277(3):733-40.
Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up.
Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. Cancer Imaging. 2014 Nov 12; 14:30.
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23.
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Transl Oncol. 2015 Jun; 8(3):147-53.
[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.
Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya NH, Van den Abbeele AD
Journal of the American College of Radiology : JACR
Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be. J Am Coll Radiol. 2015 Jul; 12(7):714-20.
Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be.
Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. Clin Nucl Med. 2015 Nov; 40(11):e528-9.
Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.
Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. Cancer. 2015 Nov 15; 121(22):4007-15.
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH
Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center.
Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35.
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec). PET Clin. 2008 Jan; 3(1):77-87.
FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec).
Infrequent Tumors of the Gastrointestinal Tract Including Gastrointestinal Stromal Tumor (GIST). PET Clin. 2008 Apr; 3(2):207-15.
Infrequent Tumors of the Gastrointestinal Tract Including Gastrointestinal Stromal Tumor (GIST).
Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 09; 27(9):1794-9.
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
O'Neill AC, Somarouthu B, Tirumani SH, Braschi-Amirfarzan M, Van den Abbeele AD, Ramaiya NH, Shinagare AB
Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients. Radiology. 2017 Jan; 282(1):160-170.
Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients.
Shinagare AB, Suh CH, Kim KW, Somarouthu B, Van den Abbeele AD, Ramaiya NH
Ovarian Cancer: An Evidence-Based, Easy-to-Use Prediction Rule to Optimize the Use of Follow-up Chest CT. J Am Coll Radiol. 2017 Apr; 14(4):499-508.
Ovarian Cancer: An Evidence-Based, Easy-to-Use Prediction Rule to Optimize the Use of Follow-up Chest CT.
Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A
Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology. Stat. 2014 Jan 01; 3(1):172-186.
Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology.
O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT
Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503.
Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.
Jacobsen E, Van Den Abbeele AD, Neuberg D, Li S, Fisher DC, Friedberg J, Barnes AS, Yap JT, Kutok J, Freedman AS
Inhibiting TNFa with etanercept in relapsed/refractory follicular lymphoma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):17525.
Inhibiting TNFa with etanercept in relapsed/refractory follicular lymphoma.
Van Den Abbeele AD, Barnes AS, De Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD
Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3087.
Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST).
Raut CP, Van Den Abbeele A, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD
Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9547.
Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).
Lin NU, Carey LA, Liu MC, Younger J, Come SE, Bullitt E, Van Den Abbeele AD, Li X, Hochberg FH, Winer EP
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):503.
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer.
Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot Barnes A, Yap JT, Godwin AK, Blevins M, Eisenberg B, Siegel BA
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. J Clin Oncol. 2009 May 20; 27(15_suppl):10552.
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression.
Urban T, Sadow CA, Cleary JM, Harris GJ, Van Den Abbeele AD
Impact of RECIST 1.1 modifications on clinical trial eligibility. J Clin Oncol. 2011 May 20; 29(15_suppl):e16555.
Impact of RECIST 1.1 modifications on clinical trial eligibility.
Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke C, Von Mehren M, Joensuu HT, Dimitrijevic S, Demetri GD, Van Den Abbeele AD
Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3011.
Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).
Van Den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, Armand MS, Baum C, Demetri GD
Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3012.
Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.
Lin NU, Mayer IA, Najita JS, Hobday TJ, Falkson CI, Dees EC, Rimawi MF, Nanda R, Gelman RS, Josephs K, Richardson A, Flores L, Van Den Abbeele AD, Yap JT, Arteaga CL, Wolff AC, Krop IE, Winer EP
TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC). J Clin Oncol. 2011 May 20; 29(15_suppl):527.
TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+ metastatic breast cancer (MBC).
Hodi FS, Friedlander PA, Atkins MB, McDermott DF, Lawrence DP, Ibrahim N, Wu X, Zhou J, Giobbie-Hurder A, Murphy G, Hollman T, Velazquez E, Russell S, Dipiro P, Yap JT, Van Den Abbeele AD
A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2011 May 20; 29(15_suppl):8511.
A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma.
George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Manola J, Yap JT, Van Den Abbeele AD, Solomon S, Fletcher JA, Demetri GD
A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 May 20; 29(15_suppl):10007.
A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
Van Oosterom AT, Dumez H, Desai J, Stroobants S, Van Den Abbeele AD, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3002.
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.
Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van Den Abbeele A, Baum C, Maki R, Heinrich MC
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
Van Den Abbeele AD, Tanaka Y, Locascio T, Sakellis C, Heinrich MC, von Mehren M, Choy E, Tap WD, Manola J, Demetri GD, George S, Yap JT
Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J Clin Oncol. 2011 May 20; 29(15_suppl):10050.
Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).
Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van Den Abbeele A, Silverman SG, Demetri GD
Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9024.
Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM).
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van Den Abbeele AD, Vansonnenberg E, Demetri GD
Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions.
Wu C, Vasconcelles M, DePiro P, Van den Abbeele A, Rakusin A, Bechard K, Skarin A
Primary cardiac angiosarcoma presenting as a malignant pericardial effusion. J Clin Oncol. 1998 Dec; 16(12):3913-5.
Primary cardiac angiosarcoma presenting as a malignant pericardial effusion.
Janicek MJ, Van den Abbeele AD, DeSisto WC, Kassis AI, Holman BL, Tumeh SS, Hollenberg NK
Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography. Invest Radiol. 1991 Jul; 26(7):655-9.
Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography.
Slavin SA, Upton J, Kaplan WD, Van den Abbeele AD
An investigation of lymphatic function following free-tissue transfer. Plast Reconstr Surg. 1997 Mar; 99(3):730-41; discussion 742-3.
An investigation of lymphatic function following free-tissue transfer.
Van den Abbeele AD, Yap JT, Rastarhuyeva I, Akhurst T, Keohan ML, George S, Bhuchar G, Morgan JA, Demetri GD, Maki RG
Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. J Clin Oncol. 2008 May 20; 26(15_suppl):10529.
Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET.
Wagner AJ, Morgan JA, Chugh R, Rosen LS, George S, Gordon MS, Devine CM, Van den Abbeele AD, Grayzel D, Demetri GD
Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10503.
Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial.
Evans TR, Morgan JA, van den Abbeele AD, McPherson IR, George S, Crawford D, Mastrullo JM, Cheng S, Fletcher JA, Demetri GD
Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3034.
Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors.
Ross RW, Manola J, Oh WK, Ryan C, Kim J, Rastarhuyeva I, Yap JT, Van Den Abbeele AD, Kantoff PW, Taplin M
Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol. 2008 May 20; 26(15_suppl):5069.
Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity.
Zondervan RL, Van den Abbeele AD, Barish MA, Urban T, Oliveira GR, Braschi M, Hanlon WB, Frenkel V, Harris GJ
Tumor imaging metrics core: A centralized service for standardized tumor measurements at a multi-institutional collaborative cancer center. J Clin Oncol. 2008 May 20; 26(15_suppl):20571.
Tumor imaging metrics core: A centralized service for standardized tumor measurements at a multi-institutional collaborative cancer center.
van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri G
Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9006.
Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST).
Oliveira GR, Zondervan RL, Van Den Abbeele AD, Barish MA, Urban T, Braschi M, Frenkel V, Hanlon WB, Harisinghani MG, Harris GJ
The impact of large lesions on the RECIST assessment criteria. J Clin Oncol. 2008 May 20; 26(15_suppl):17560.
The impact of large lesions on the RECIST assessment criteria.
Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD
When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy? J Nucl Med. 2000 Feb; 41(2):269-74.
When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
Bartold SP, Donohoe KJ, Fletcher JW, Haynie TP, Henkin RE, Silberstein EB, Royal HD, Van den Abbeele A
Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. J Nucl Med. 1997 Jun; 38(6):990-4.
Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine.
Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD
Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
McIntosh LJ, O'Neill AC, Bhanusupriya S, Matalon SA, Van den Abbeele AD, Ramaiya NH, Shinagare AB
Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer. Abdom Radiol (NY). 2017 10; 42(10):2513-2520.
Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.
McCollum AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case MA, Posner MR, Van den Abbeele AD
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.
Frank DA, Meuse J, Hirsch D, Ibrahim JG, van den Abbeele AD
The treatment and outcome of cancer patients with thromboses on central venous catheters. J Thromb Thrombolysis. 2000 Dec; 10(3):271-5.
The treatment and outcome of cancer patients with thromboses on central venous catheters.
Jacobson AF, Shapiro CL, Van den Abbeele AD, Kaplan WD
Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer. 2001 Jan 01; 91(1):17-24.
Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma.
Vascular Scintigraphy. Teaching Atlas of Nuclear Medicine. 2000; 429-439.
Kassis AI, Tumeh SS, Wen PYC, Baranowska-Korylewicz J, Van den Abbeele AD, Zimmerman RE, Carvalho PA, Garade BM, DeSisto WC, Baily NO, Castronovo FP,Mariani G, Black PMcL, Adelstein SJ.
Adelstein SJ, Kassis AI, eds. Processing of symposium on clinical application of radiolabeled IUdR.
Intratumoral administration of 5-[123/]iodo-2-deoxyurdine in a patients with a brain tumor. Adelstein SJ, Kassis AI, eds. Processing of symposium on clinical application of radiolabeled IUdR. 1996; 37:(Suppl) 19S-22S.
Intratumoral administration of 5-[123/]iodo-2-deoxyurdine in a patients with a brain tumor
Wagenaar DJ, Golden E, Van den Abbeele AD, kolodny GM.
Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer
Determinination of the visibility of simulated lesions in background with 511 KeV SPECT. Proceedings of the European Conference on Research and Application of Positron Emission Tomography in Oncology PET and Cancer. 1996.
Determinination of the visibility of simulated lesions in background with 511 KeV SPECT
A prospective blind comparison of positron emission tomography (PET) with gallium/SPECT scintigraphy in the staging and follow up of patients with de novo Hodgkin's disease. 2001.
A prospective blind comparison of positron emission tomography (PET) with gallium/SPECT scintigraphy in the staging and follow up of patients with de novo Hodgkin's disease
Ji H.; Khosa F.; Van den Abbeele A. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School., Boston, MA
Primary Malignant Neoplasms Mimicking Peritoneal Carcinomatosos: CT, MRI, and 18F FDG PET/CT Findings. American Journal of Roentgenology(AJR). 2007; 188(5):E207-A125-A140.
Primary Malignant Neoplasms Mimicking Peritoneal Carcinomatosos: CT, MRI, and 18F FDG PET/CT Findings
Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz, Jones PL, Lambrecht RM, Adelstein SJ, Black PMcL, Kassis AI.
Presented at the Australia/ New Zealand Society of Nuclear Medicine scientific Meeting.
A three-step procedure for the targeting of tumors using the avidin-biotin system. Presented at the Australia/ New Zealand Society of Nuclear Medicine scientific Meeting. 1993.
Khawli LA, van den Abbeele AD, Kassis AI
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology
N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B. 1992 Apr; 19(3):289-95.
N-(m-[125I]iodophenyl)maleimide: an agent for high yield radiolabeling of antibodies.
Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007 Dec; 189(6):W324-30.
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
Kassis AI, Wen PY, Van den Abbeele AD, Baranowska-Kortylewicz J, Makrigiorgos GM, Metz KR, Matalka KZ, Cook CU, Sahu SK, Black PM, Adelstein SJ
5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats. J Nucl Med. 1998 Jul; 39(7):1148-54.
5-[125I]iodo-2'-deoxyuridine in the radiotherapy of brain tumors in rats.
Baranowska-Kortylewicz J, Makrigiorgos GM, Van den Abbeele AD, Berman RM, Adelstein SJ, Kassis AI
5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model. Int J Radiat Oncol Biol Phys. 1991 Nov; 21(6):1541-51.
5-[123I]iodo-2'-deoxyuridine in the radiotherapy of an early ascites tumor model.
Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J
Journal of the National Comprehensive Cancer Network : JNCCN
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res. 2007 Oct 15; 13(20):6175-81.
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG
Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res. 1990 Apr 01; 50(7):2198-202.
Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.
The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist. 2008; 13 Suppl 2:8-13.
The lessons of GIST--PET and PET/CT: a new paradigm for imaging.
Masciari S, Van den Abbeele AD, Diller LR, Rastarhuyeva I, Yap J, Schneider K, Digianni L, Li FP, Fraumeni JF, Syngal S, Garber JE
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9.
F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma. Clin Nucl Med. 2008 Aug; 33(8):545-6.
F-18 FDG PET/CT in the diagnosis and management of a pericardiac paraganglioma.
Losken A, Swartz MA, Van Den Abbeele AD, Jain RK, Slavin SA
A potential murine model for flap-related investigations. Plast Reconstr Surg. 2001 May; 107(6):1504-8.
A potential murine model for flap-related investigations.
Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71.
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Kassis AI, Van den Abbeele AD, Wen PY, Baranowska-Kortylewicz J, Aaronson RA, DeSisto WC, Lampson LA, Black PM, Adelstein SJ
Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res. 1990 Aug 15; 50(16):5199-203.
Specific uptake of the auger electron-emitting thymidine analogue 5-[123I/125I]iodo-2'-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans.
Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH
Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72.
Atypical metastases from prostate cancer: 10-year experience at a single institution.
Mariani G, Abbeele AD, Venkateshan CN, Kaldany A, Ito S, Adelstein SJ, Kassis AI
Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications. Int J Rad Appl Instrum B. 1989; 16(2):147-50.
Monoclonal antibody internalization by tumor cells: an experimental model for potential radioimmunotherapy applications.
Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD
Imaging of lung cancer in the era of molecular medicine. Acad Radiol. 2011 Apr; 18(4):424-36.
Imaging of lung cancer in the era of molecular medicine.
Holdsworth CH, Badawi RD, Santos PA, Van den Abbeele AD and EI Fakhri G.
Evaluation of a Monte Carlo scatter correction in clinical 3D PET. IEEE Medical Imaging Conference. 2003.
Evaluation of a Monte Carlo scatter correction in clinical 3D PET
Badawi RD, El Fakhri G, Lechpammer S, Spangler TA, Tetrault RJ, Moore SC, Van den Abbeele AD.
A comparison of 2D and 3D FDG-PET images on a high performance BGO scanner using an interleaved septa-in/septa-out acquisition protocol. Molecular Imaging and Biology. 2002; 4:44S.
A comparison of 2D and 3D FDG-PET images on a high performance BGO scanner using an interleaved septa-in/septa-out acquisition protocol
Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004 Jan; 45(1):85-92.
FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.
Van Oosteram AT, Dumez H, Desai J, Stroobants S, Van den Abbeele A, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD.
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM. American Society of Clinical Oncology (ASCO) Conference; New Orleans, LA. 2004.
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001)and imatinib mesylate (IM, Glivac/Gleevac) in patients with gastrointestinal stromal tumor (GIST)refractory to IM
Layne WW, Kassis AI, Van den Abbeele A, Kinsey BM, Adelstein SJ
HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G. J Immunol Methods. 1987 Feb 11; 96(2):195-9.
HPLC analysis of the dissociation and recombination of rabbit immunoglobulin G.
Krajewski KM, Howard SA, Shinagare AB, Van den Abbeele AD, Fennessy FM
Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era. J Am Coll Radiol. 2017 10; 14(10):1345-1348.
Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era.
van den Abbeele AD, Aaronson RA, Taube RA, Adelstein SJ, Kassis AI
The Journal of nuclear medicine and allied sciences
Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios. J Nucl Med Allied Sci. 1990 Apr-Jun; 34(2):94-102.
Preadsorption of radiolabeled monoclonal antibodies to liver and spleen tissues leads to higher tumor-to-normal-tissue ratios.
Kinsey BM, Van den Abbeele AD, Adelstein SJ, Kassis AI
Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts. Cancer Res. 1989 Nov 01; 49(21):5986-8.
Absence of preferential uptake of [125I]iododihydrorhodamine 123 by four human tumor xenografts.
Kuppens S, Bossaert G, Buntinx W, Molleman C, Van den Abbeele A, Maes B
American journal on intellectual and developmental disabilities
Factorial validity of the Supports Intensity Scale (SIS). Am J Intellect Dev Disabil. 2010 Jul; 115(4):327-39.
Factorial validity of the Supports Intensity Scale (SIS).
Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. Acad Radiol. 2011 Jan; 18(1):54-62.
CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.
Van den Abbeele AD, Baranowska-Kortylewicz J, Adelstein SJ, Carvalho PA, Tutrone RF, Riche JP, Wen PYC, Black PMcL, Mariani G Kassis AI.
In Howell RW, Narra VR, Sastry KSR, Rao DV, eds Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8.
Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer. In Howell RW, Narra VR, Sastry KSR, Rao DV, eds Biophysical aspect of Auger processes, AAPM Symposium Proceeding number 8. 1992; 372-395.
Diagnostic and therapeutic application of Auger-electrons-emitting 5[123/125]iodo-2-deoxyuridine in cancer
Malignant Melanoma - Not Just Skin Deep!. American Journal of Roentgenology(AJR). 2007; 188(5):E140-A115.
Malignant Melanoma - Not Just Skin Deep!
G. D. Demetri, S. George, J. A. Morgan, A. Wagner, M. T. Quigley, K. Polson, J. Pokela, A. Van den Abbeele, J. Adams, D. Grayzel; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals, Cambridge, MA
Inhibition of the heat Shock Protein 90(Hsp90) chaperone with the novel agent PIP-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase 1 trial. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):551s/10024.
Inhibition of the heat Shock Protein 90(Hsp90) chaperone with the novel agent PIP-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST: Updated results of a phase 1 trial
Advances at the Frontier of Cancer Diagnosis: PET scanner opens a window on cancer. Paths of Progress. 2000.
Advances at the Frontier of Cancer Diagnosis: PET scanner opens a window on cancer
Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK
Immune Modulation Therapy and Imaging: Workshop Report. J Nucl Med. 2018 03; 59(3):410-417.
Immune Modulation Therapy and Imaging: Workshop Report.
George D, Febbo P, Hagman E, OH W, Gilligan T, Lofa M, Weinstein M, Badawi RD, Van den Abbeele AD, Tempany C, Moricz M, Silberman S, Riche J, Kantoff P and Bubley G.
A Pilot study Imatinib Mesylate prior to prostatectomy in men with newly diagnosed prostate cancer. 2002.
A Pilot study Imatinib Mesylate prior to prostatectomy in men with newly diagnosed prostate cancer
Souza FF, Fennessy FM, Yang Q, van den Abbeele AD
Case report. PET/CT appearance of desmoid tumour of the chest wall. Br J Radiol. 2010 Feb; 83(986):e39-42.
Case report. PET/CT appearance of desmoid tumour of the chest wall.
Blanke C, Joensuu H, Demetri G, Heninrich M, Roberts P, Eisenberg B Fletcher J, Fletcher C, Corless C, Dimitrijevic S, Van den Abbeele A, Kiese B, McDougall K, von Mehren M.
Long-term follow upof advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib mesylate. Gastointestinal Cancers Symposium . 2004.
Long-term follow upof advanced gastrointestinal stromal tumors (GIST) patients treated with imatinib mesylate
EI Fakhri G, Holdsworth CH, Santos PA, Badawi RD, Van den Abbeele AD and Kijewski MF.
Impact of patient size, aquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estmiation in whole-body FDG-PET. IEEE Medical Imaging Conference. 2003.
Impact of patient size, aquisition mode, reconstruction algorithm, and randoms and attenuation corrections on lesion detection and activity estmiation in whole-body FDG-PET
Van den Abbeele AD, Aaronson RA, Daher S, Taube RA, Adelstein SJ, Kassis AI
Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction. J Nucl Med. 1991 Jan; 32(1):116-22.
Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction.
European journal of cancer (Oxford, England : 1990)
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002 Sep; 38 Suppl 5:S60-5.
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD
Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005 Jun; 235(3):892-8.
Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants. Mol Imaging Biol. 2005 May-Jun; 7(3):244-56.
2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography of the head and neck: an atlas of normal uptake and variants.
Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA
Current problems in diagnostic radiology
Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
Surveillance Imaging in Patients With Endometrial Cancer in First Remission.
Shinagare AB, Jagannathan JP, Ramaiya NH, Hall MN, Van den Abbeele AD
Adult extragonadal germ cell tumors. AJR Am J Roentgenol. 2010 Oct; 195(4):W274-80.
Suh CH, Shinagare AB, Westenfield AM, Ramaiya NH, Van den Abbeele AD, Kim KW
Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis. Clin Radiol. 2018 02; 73(2):158-167.
Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis.
George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Ji H.; Fennessyu F.; Van den Abbeele A.; Ros P. Department of Radiology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Lymphoma: Differentiation of Lymphoma from Other Conditions. American Journal of Roentgenology(AJR). 2007; 188(5):A125.
Lymphoma: Differentiation of Lymphoma from Other Conditions
Raut CP, Van den Abbeele AD, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD
Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology. 2006; 24:531s.
Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST)
Gangopadhyay A, Van den Abbeele AD, Kassis AI
Modification of Mouse IgG isoelectric point following radioiodination. Antibody Immunoconj Radiophar. 1994; 7:171-178..
Modification of Mouse IgG isoelectric point following radioiodination
Van den Abbeele AD, Craveiro EM, Manganella JH, Kaplan WD.
Lymphatic imaging and its multiple roles in clinical practice. J Nucl Med. 1995; 36:P222.
Lymphatic imaging and its multiple roles in clinical practice
Radiological Society of North America (RSNA)Conference.
Physiologic and benign causes of FDG uptake in oncologic FDG-PET imaging. Radiological Society of North America (RSNA)Conference. 2003.
Van den Abbeele AD, Badawi RD, Cliche JP, Spangler T, Janicek MJ, Israel DA, Heinrich MC, Silberman SS, Dimitrijevic S, Demetri GD.
FDG-PET as a Surrogate Marker for the Response to Gleevec (Imatinib Mesylate) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST). J Nucl Med. 2003; 44(5):24-25.
FDG-PET as a Surrogate Marker for the Response to Gleevec (Imatinib Mesylate) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, Harris GJ, Bullitt E, Van den Abbeele AD, Henson JW, Li X, Gelman R, Burstein HJ, Kasparian E, Kirsch DG, Crawford A, Hochberg F, Winer EP
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
Metabolic imaging of cancer. Proceedings of the Europeans Conference on Research and Application of Positron Emission Tomography in Oncology.
Determination of the visibility of simulated lesions in background with 511 KeV SPECT. In Paans AMJ, Pruim J, Franssen EJF, Vaalburg W, eds.+. Metabolic imaging of cancer. Proceedings of the Europeans Conference on Research and Application of Positron Emission Tomography in Oncology. 1996.
Determination of the visibility of simulated lesions in background with 511 KeV SPECT. In Paans AMJ, Pruim J, Franssen EJF, Vaalburg W, eds.+
Van den Abbeele AD, Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Mauch P and Canellos GP.
FDG-PET is superior to gallium-67 scintigraphy in the staging and follow-up of patients with Hodgkin's disease: a prospective, blinded comparison. J Nucl Med. 2002; 43:P30-P31.
FDG-PET is superior to gallium-67 scintigraphy in the staging and follow-up of patients with Hodgkin's disease: a prospective, blinded comparison
Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van den Abbeele A, Baum C, Maki R, Heinrich MC.
American Society of Clincal Oncology (ASCO) Conference.
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). New Orleans, LA. American Society of Clincal Oncology (ASCO) Conference. 2004.
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome Imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). New Orleans, LA
Urban T, Ziegler E, Lewis R, Hafey C, Sadow C, Van den Abbeele AD, Harris GJ
LesionTracker: Extensible Open-Source Zero-Footprint Web Viewer for Cancer Imaging Research and Clinical Trials. Cancer Res. 2017 11 01; 77(21):e119-e122.
LesionTracker: Extensible Open-Source Zero-Footprint Web Viewer for Cancer Imaging Research and Clinical Trials.
The role of PET in patients with GIST. 2001.
T. Locascio, Y. Kuzuhara, L. Syrkin, D. J. de Vries, G. Lefever, A. D. Van den Abbbeele, J. T. Yap, Division of Nuclear Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts.(334084)
PET/CT quality assurance in clinical trials and good clinical practice. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):448P/2012.
PET/CT quality assurance in clinical trials and good clinical practice
Mariani G, Ito S, Nayak RC, Baranowska-Kortylewicz J, Venkateshan CN, Van den Abbeele AD, Eisenbarth GS, Adelstein SJ, Kassis AI
Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells. J Nucl Biol Med (1991). 1991 Apr-Jun; 35(2):111-9.
Capping and internalization of a monoclonal antibody-surface antigen complex: a possible mode of interaction of monoclonal antibodies and tumor cells.
Adelstein SJ, Kassis AI, Baranowska-Kortylewicz J, van den Abbeele AD, Mariani G, Ito S
Potential for tumor therapy with iodine-125 labeled immunoglobulins. Int J Rad Appl Instrum B. 1991; 18(1):43-4.
Potential for tumor therapy with iodine-125 labeled immunoglobulins.
Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
PET scanner is enhancing cancer diagnosis. 2000.
PET scanner is enhancing cancer diagnosis
Van den Abbeele AD, for the GIST Collaborative PET Study Group.
F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol. 2001; 20:P362a.
F18-FDG-PET provides early evidence of biological response to ST1571 in patients with malignant gastrointestinal stromal tumors (GIST)
Van den Abbeele AD, Rybicki FJ, Cowart DM, Kehoe KM.
Quantification of gallium-67 avidity as a function of the histology in patients with non-Hodgkin's lymphoma. J Nucl Med. 1997; 38:P238.
Quantification of gallium-67 avidity as a function of the histology in patients with non-Hodgkin's lymphoma
Scintigraphy of neoplastic disease. Teaching Atlas of Nuclear Medicine. Donohoe K, Van den Abbeele. 2000; 224-234.
Manning WC, Bello CL, DePrimo SE, Fletcher JA, Fletcher CDM, Van den Abbeele AD, Cohen DP, Scigalla P, Cherrington JM, Demetri GD.
Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol. 2003; 22:192A.
Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST)
Sheehy N, Fennessy F, Van den Abbeele A D
The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma. Seminars in Colon and Rectal Surgery. 2007; In Press.
The Utility of 18F-FDG-PET in the Diagnosis and Management of Colorectal Carcinoma
Mariani G, Cei A, Collecchi P, Baranowska-Kortylewicz J, Van den Abbeele AD, Di Luca L, Di Stefano R, Viacava P, Ferdeghini EM, Di Sacco S
Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med. 1993 Jul; 34(7):1175-83.
Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2'-deoxyuridine following intratumoral injection in patients with colorectal cancer.
Van den Abbeele AD, Baranowska-Kortylewicz J, Mariani G, Adelstein SJ, Kassis Al.
Second International Symposium on Biophysical Aspects of Auger Processes, Amherst, MA
Diagnostic and therapeutic applications of the Auger electron-emitting 5-[123/125/]iodo-2'-deoxyuridine in cancer. Second International Symposium on Biophysical Aspects of Auger Processes, Amherst, MA. 1991.
Diagnostic and therapeutic applications of the Auger electron-emitting 5-[123/125/]iodo-2'-deoxyuridine in cancer
Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis Al.
Abstracts of the Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan
A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium on Radiopharmaceutical Chemistry, Kyoto, Japan. 1993; 392(3).
A new three-step strategy using the avidin-biotin system for radioimaging tumors
Wagenaar DJ, Van den Abbeele AD, Kolodny GM, Hill TC, Zimmerman RE.
A world wide web-based resource for the physical evaluation of 511 keV-collimated imaging. J Nucl Med. 1996; 37:P305.
A world wide web-based resource for the physical evaluation of 511 keV-collimated imaging
El Fakhri G, Holdsworth C, Badawi RD, Santos PA, Kijewski MF, Van den Abbeele AD, Moore SC.
Dependence of performace of whole-body-FDG-PET lesion detection and activity estimation on patient size, randoms, variance reduction, and acquisition geometry. J Nucl Med. 2003; 44(5):61.
Dependence of performace of whole-body-FDG-PET lesion detection and activity estimation on patient size, randoms, variance reduction, and acquisition geometry
American Society of Clinical Oncology (ASCO) Conference.
Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM. American Society of Clinical Oncology (ASCO) Conference. 2004.
Combination signal transduction inhibition: a phase 1 and 2 trial of the oral mTOR-inhibitor everolimus (ERAD001) and imatinib mesylate (IM, Glivac r/Gleevac r) in patients (pts) with gastrointestinal stromal tumor (GIST) refactory to IM
McCollum AD, Van den Abbeele AD, Haddad RI, Burrell SC, Norris CM, Tishler RB, Case MA, Posner MR.
Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Virginia
The use of FDG-PET to detect residual disease after induction chemotherapy and definite chemoradiotherapy for squamous cell cancer of the head and neck. Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer. Virginia. 2000.
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A
Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma. 2008 May; 49(5):902-9.
Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept.
El Fakhri G, Santos PA, Badawi RD, Holdsworth CH, Van Den Abbeele AD, Kijewski MF
Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET. J Nucl Med. 2007 Dec; 48(12):1951-60.
Impact of acquisition geometry, image processing, and patient size on lesion detection in whole-body 18F-FDG PET.
Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
Dileo P, Van den Abbeele AD, Manola J, Desai J, Morgan JA, George S, St. Armand MW, Baum C, Demetri GD
American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; Hollywood, FL.
Qualitative assessment of FDG PET correlates with clinical benefit in patients with imatinib mesylate-resistant GIST treated with multi-targeted tyrosine kinase inhibitor SU11248. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; Hollywood, FL. 2005.
Qualitative assessment of FDG PET correlates with clinical benefit in patients with imatinib mesylate-resistant GIST treated with multi-targeted tyrosine kinase inhibitor SU11248
McCollum D, Van den Abbeele AD, Burrell SC, Haddad RI, Norris CM, Tishler RB, Case Ma, Lake-Willcutt B, Posner MR.
The second International Chicago Symposium on Malignancies of the Chest and Head and neck.
The use of FDG-PET to detect residual disease after sequential therapy with induction chemotherapy and definitive chemoradiotherapy for squamous cell cancer of the head and neck. The second International Chicago Symposium on Malignancies of the Chest and Head and neck. 2001.
Van den Abbeele AD, Aaronson RA, Adelstein SJ, Kassis AI
Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior? J Nucl Med Allied Sci. 1988 Oct-Dec; 32(4):260-7.
Does the in vitro testing of the immunoreactivity of an antibody reflect its in vivo behavior?
Van den Abbeele AD, Barnes AS, de Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD
Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). American Society of Clinical Oncology (ASCO). 2006; 24:142s.
Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST)
Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri G
Clonal Evolution of Resistance to Imatinib in Patients with Metastic GIST: Molecular and Radiologic Evaluation of New Lesions. 2006.
Clonal Evolution of Resistance to Imatinib in Patients with Metastic GIST: Molecular and Radiologic Evaluation of New Lesions
Moore SC, EI Fakhri G, Badawi R, Van den Abbeele AD, Zimmerman RE.
Relative Lesion detectability in 3D vs. 2D dedicated multi-ring PET. 2000.
Relative Lesion detectability in 3D vs. 2D dedicated multi-ring PET
Smith SV, Van den Abbeele AD, Baranowska-Kortylewicz J, Jones PL, Lambrecht RM, Adelstein SJ, Kassis AI.
Abstracts of the Tenth International Symposium in Radiopharmaceutical Chemistry,
A new three-step strategy using the avidin-biotin system for radioimaging tumors. Abstracts of the Tenth International Symposium in Radiopharmaceutical Chemistry,. 1993; 392-3.
Otero HJ, Jagannathan JP, Prevedello LM, Johnston CJ, Ramaiya NH, Van den Abbeele AD, DiPiro PJ
CT and PET/CT findings of T-cell lymphoma. AJR Am J Roentgenol. 2009 Aug; 193(2):349-58.
CT and PET/CT findings of T-cell lymphoma.
Lee AI, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP
Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer. 2010 Aug 15; 116(16):3835-42.
Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis.
Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, DiPiro PJ, Nishino M
Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center. Cancer. 2011 Aug 15; 117(16):3860-6.
Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center.
PET documents Gleevec tumor-fighting power. Diagnostic Imaging. 2001; 1(2):4.
PET documents Gleevec tumor-fighting power
Monoclonal antibodies: From basics to clinical implementation.
Monoclonal antibodies: From basics to clinical implementation. 1993.
Monoclonal antibodies: From basics to clinical implementation
Demetri GD, Benjamin R, Blanke CD, Haesun C, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CDM, Maki RG, Rubin B, Van den Abbeele AD, vonMehren M.
Optimal management of patients with gastrointestinal stromal tumors (GIST).
Optimal management of patients with gastrointestinal stromal tumors (GIST). 2004.
Optimal management of patients with gastrointestinal stromal tumors (GIST)
Desai J, Shankar S, Heinrich MC, Fletcher CD, Tuncali K, Silverman SG, Van den Abbeele AD, vanSonnenberg E, Demetri GD.
Molecular and radiologic evalution of new lesions. American Society of clinical Oncology (ASCO) Conference.
Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST). Molecular and radiologic evalution of new lesions. American Society of clinical Oncology (ASCO) Conference. 2004.
Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST)
Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease. J Natl Compr Canc Netw. 2008 Jul; 6(6):623-32.
Role of PET/CT scanning in initial and post-treatment assessment of Hodgkin disease.
Engelhardt B, Sandberg K, Bratton D, Van den Abbeele A, Grogaard J, Hellerqvist C, Sundell H
The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs. Pediatr Res. 1987 Feb; 21(2):159-65.
The role of granulocytes in the pulmonary response to group B streptococcal toxin in young lambs.
Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I
Hematology/oncology clinics of North America
Imaging in renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):687-715.
Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Van den Abbeele AD, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi RD, Demetri GD
The European Cancer Conference (ECCO 13); Paris, France.
FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate. The European Cancer Conference (ECCO 13); Paris, France. 2005.
FDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate
A. D. Van den Abbeele, J. T. Yap, D. S. Grayzel, J. Walker, G. D. Demetri; Dana-Farber Cancer Institute, Boston, MA; Infinity Pharmaceuticals Inc., Cambridge, MA
Inhibition and flare patterns of metabolic response to the heat shock protein 90(Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy. Journal of Clinical Oncology (JCO). 2007; 25(18S Part 1 of 2):145s/3530.
Inhibition and flare patterns of metabolic response to the heat shock protein 90(Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy
Slavin SA, Van den Abbeele AD, Losken A, Swartz MA, Jain RK
Return of lymphatic function after flap transfer for acute lymphedema. Ann Surg. 1999 Mar; 229(3):421-7.
Return of lymphatic function after flap transfer for acute lymphedema.
Positron Emission Tomography Imaging for Tumor Ablation. Tumor Ablation: Principles and Practice. 2005; 121-134..
Positron Emission Tomography Imaging for Tumor Ablation
Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, Van den Abbeele A, Yap J, Sullivan D
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med. 2006 Jun; 47(6):1059-66.
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
Van den Abbeele AD, Treves ST, Lebowitz RL, Bauer S, Davis RT, Retik A, Colodny A
Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography. Pediatrics. 1987 Jan; 79(1):147-53.
Vesicoureteral reflux in asymptomatic siblings of patients with known reflux: radionuclide cystography.
Positron Emission Tomography (PET). 2000.
Van den Abbeele AD, Shulkin BL, Neuberg DS, Kehoe KM.
The role of SPECT in the evaluation of the abdomen on gallium-67 scintigraphy. J Nucl Med. 1997; 38:P115.
The role of SPECT in the evaluation of the abdomen on gallium-67 scintigraphy
Dileo P, Bauer S, Van den Abbeele AD, Morgan JA, George S, Salesi JM, Veronese L, Manley P, Fletcher JA, Demetri GD
Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST. American Society of Clinical Oncology (ASCO): Gastrointestinal Cancers Symposium; San Francisco, CA. 2006.
Results with AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): preclinical rationale and early results in a patient (Pt) with imatinib (IM)-resistant GIST
G. Lefever, E. Andersen, J. T. Yap, A. D. Van den Abbeele, R. Tetrault; 1. Nucleare Medicine; 2. Environmental Health and Safety, Dana-Farber Cancer Institute, Boston, Massachusetts.(335244)
Practical methods to minimize occupational radiation exposures in PET and nuclear medicine. Journal of Nuclear Medicine(JNM). 2007; 48(Abstract Book):452 p/2024.
Practical methods to minimize occupational radiation exposures in PET and nuclear medicine
Borras-Boneu G, Van den Abbeele AD, Kassis AI.
Proceeding of the Fourth International Conference on Monoclonal Antibody lmmunoconjugates for Cancer.
Biodistribution of radiolabeled MOv18 in nude mice bearing ovarian cancer xenografts. Proceeding of the Fourth International Conference on Monoclonal Antibody lmmunoconjugates for Cancer. 1998; 97.
Khosa F.; Ramaiya N.; Johnston C.; Disalvo D.; Jagannathan J.; Van den Abbeele A.D. Dana-Farber Cancer Institute, Boston, MA
Imaging of Venous Thrombosis in Oncologic Patients. American Journal of Roentgenology(AJR). 2007; 188(5):E136-A115.
Imaging of Venous Thrombosis in Oncologic Patients
Cherrington JM, Van den Abbeele A, Badawi RD, Lechpammer S, McCarthy TJ, Corless CL, ChoenDP, Scigalla P, Fletcher JA, and Demetri GD.
Pharmacodynamic evaluation using 18 FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers.
Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib -resistant gastrointestinal stromal tumors (GIST):. Pharmacodynamic evaluation using 18 FDG-PET functional imaging, pharmacokinetics, and modulation of blood biomarkers. 2003.
Assessing biological responses to SU11248 in a Phase I clinical trial of patients with imatinib -resistant gastrointestinal stromal tumors (GIST):
Demetri GD, Heinrich MC, Fletcher JA, Fletcher CDM, George S, Desai J, Cohen DP, Scigalla P, Cherrington JM, Van den Abbeele AD.
Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol. 2003; 22:814A.
Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients with malignant gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate
Van den Abbeele AD, Hardoff R, Royal HD, Kolodny GM
Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy. Clin Nucl Med. 1987; 12:954-5..
Bone metastases in Zollinger-Ellison syndrome: detection by bone scintigraphy